NEUROPHYXIA

Neurophyxia is an innovative clinical-stage drug development company, developing novel drugs to reduce the deleterious effects of oxygen shortage in the brain... Neurophyxia was founded in 2008 and is headquartered in 's-Hertogenbosch, the Netherlands. The company has developed a novel neuroprotectant from early preclinical phase upto current Phase IIb/III Clinical Development, thanks to its dedicated academic team, backed-up by strong business and investment partners... Neurophyxia is developing 2-iminobiotin (2-IB) for the treatment of cerebral hypoxie ischemia and subsequent reperfusion injury following Stroke, Cardiac Arrest and Birth Asphyxia.

Also known as: Neurophyxia BV